NYSE - Delayed Quote • USD
Penumbra, Inc. (PEN)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 15 | 15 |
| Avg. Estimate | 0.38 | 0.61 | 2.82 | 3.84 |
| Low Estimate | 0.3 | 0.45 | 2.54 | 3.44 |
| High Estimate | 0.61 | 0.72 | 3.04 | 4.35 |
| Year Ago EPS | 0.23 | 0.43 | 2.09 | 2.82 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 14 | 14 |
| Avg. Estimate | 274.89M | 301.62M | 1.25B | 1.45B |
| Low Estimate | 272.7M | 293.9M | 1.23B | 1.41B |
| High Estimate | 278M | 309.6M | 1.26B | 1.5B |
| Year Ago Sales | 229.73M | 253.22M | 1.06B | 1.25B |
| Sales Growth (year/est) | 19.70% | 19.10% | 17.70% | 16.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.11 | 0.28 | 0.45 | 0.7 |
| EPS Actual | 0.23 | 0.43 | 0.67 | 0.76 |
| Difference | 0.12 | 0.15 | 0.22 | 0.06 |
| Surprise % | 109.10% | 53.60% | 48.90% | 8.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.38 | 0.61 | 2.82 | 3.84 |
| 7 Days Ago | 0.38 | 0.61 | 2.83 | 3.85 |
| 30 Days Ago | 0.38 | 0.61 | 2.83 | 3.85 |
| 60 Days Ago | 0.54 | 0.68 | 2.84 | 3.88 |
| 90 Days Ago | 0.54 | 0.68 | 2.84 | 3.88 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | PEN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 65.20% | -- | -- | 0.80% |
| Next Qtr. | 41.90% | -- | -- | 9.60% |
| Current Year | 34.90% | -- | -- | 4.50% |
| Next Year | 36.20% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 188.35% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 1.53% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Piper Sandler: Overweight to Overweight | 4/3/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/22/2024 |
| Reiterates | Piper Sandler: Overweight to Overweight | 2/23/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 2/23/2024 |
| Reiterates | Canaccord Genuity: Buy to Buy | 2/23/2024 |
| Maintains | Truist Securities: Buy to Buy | 2/23/2024 |
Related Tickers
NARI Inari Medical, Inc.
38.64
-0.16%
NVRO Nevro Corp.
12.32
+0.24%
PODD Insulet Corporation
164.73
-0.92%
SILK Silk Road Medical, Inc
17.42
-0.23%
ITGR Integer Holdings Corporation
117.83
-0.58%
CNMD CONMED Corporation
71.08
-2.31%
IRTC iRhythm Technologies, Inc.
112.12
+0.57%
LIVN LivaNova PLC
52.76
+1.72%
INSP Inspire Medical Systems, Inc.
241.15
-0.97%
IART Integra LifeSciences Holdings Corporation
31.63
-0.97%